Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NVG-2089 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Experienced | EXPERIMENTAL | - |
| Treatment Naive | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NVG-2089 | DRUG | Study drug |
Inclusion Criteria: * Males and females at least 18 years of age at the time of signing the ICF. * Diagnosed with CIDP or Possible CIDP according to criteria of the EAN/PNS 2021 (Van den Bergh, 2021). (Diagnosis is to be confirmed by an independent adjudication committee; refer to Section 8.1.1). *...
NVG-2089 is an investigational small molecule being developed for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a neurological condition. It is currently in Phase 2 clinical development and has not been approved by the FDA.
NVG-2089 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting clinical trials to evaluate the safety, tolerability, and efficacy of NVG-2089 in patients with Chronic Inflammatory Demyelinating Polyneuropathy.
NVG-2089 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. A Phase 2 clinical trial is currently active but not recruiting participants, with an enrollment target of 60 patients.
NVG-2089 is being studied in a Phase 2 clinical trial identified as NCT07027111, titled "Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP." The trial is active but not recruiting, enrolling 60 participants aged 18 years and older in the United States.
No, NVG-2089 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Chronic Inflammatory Demyelinating Polyneuropathy. The ongoing clinical trial is assessing its safety, tolerability, and efficacy, and regulatory approval has not been granted.